Strategic Financial Concepts LLC Acquires Shares of 46,655 TG Therapeutics, Inc. (NASDAQ:TGTX)

Strategic Financial Concepts LLC acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 46,655 shares of the biopharmaceutical company's stock, valued at approximately $1,404,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TGTX. State Street Corp increased its position in shares of TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock valued at $212,712,000 after acquiring an additional 2,398,015 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of TG Therapeutics by 0.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company's stock valued at $27,708,000 after acquiring an additional 7,939 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after acquiring an additional 725,371 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock valued at $16,859,000 after acquiring an additional 270,286 shares during the last quarter. Finally, Barclays PLC grew its holdings in shares of TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after purchasing an additional 158,323 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently weighed in on TGTX shares. StockNews.com cut shares of TG Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, January 31st. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. TD Cowen started coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, TG Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $40.67.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 10.50% of the company's stock.

TG Therapeutics Stock Down 0.1 %

TG Therapeutics stock traded down $0.02 during trading on Friday, reaching $30.71. The stock had a trading volume of 1,179,306 shares, compared to its average volume of 2,259,077. The stock has a market cap of $4.78 billion, a PE ratio of -307.07 and a beta of 2.26. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 52-week low of $12.84 and a 52-week high of $36.84. The business has a 50 day moving average price of $31.15 and a 200 day moving average price of $27.31.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.